Key Points Argenx's Vyvgart franchise enjoys strong sales momentum. The company has multiple registrational data read-outs on the way. Not every Wall Street analyst likes Argenx, but most analysts do. 10 stocks we like better than Argenx Se › Even with a recent pullback, Argenx (NASDAQ: ARGX) stock remains a solid winner in 2026. Its shares are up roughly 14% year-to-date, with most of the gains coming over the last three months. Wall Street thinks that Argenx has plenty of room to run. The consensus 12-month price target for the stock indicates a potential 23% upside. Here's exactly why analysts remain bullish about this biotech stock . Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.